Lupin to supply TB drugs to GSK Philippines

Lupin has entered into an agreement with GSK Philippines whereby Lupin will manufacture and supply its anti-TB formulations to GSK for marketing in Philippines. The TB drugs of Lupin are based on WHO dosing guidelines.

Philippines ranks eighth among 22 countries with a high-burden of tuberculosis incidence. According to the World Health Organization's Tuberculosis Control: WHO Report 2004, there were more than 251,000 cases in the Philippines in 2002, with an estimated incidence rate of 320 per 100,000 people.

The Lupin-GSK arrangement seeks to leverage intellectual property and technology of Lupin in TB medication, with strong distribution and marketing infrastructure of GSK in the Philippines.

Kamal Sharma, managing director of Lupin said, "This arrangement is a further step forward in Lupin's quest to make available TB drugs efficiently to the geographies most afflicted with the disease".

Based in Mumbai, Lupin develops, manufactures and markets generic intermediates, active pharmaceutical ingredients and finished dosages.